Symbiotec Pharmalab IPO Closes on Day 4 With Overall Subscription at 75.08x; QIB Portion Booked 181.20x

Mumbai, August 27: The Symbiotec Pharmalab IPO has closed for subscription after a strong four-day bidding period that saw demand accelerate sharply on the final day. The ₹1,757 crore IPO was subscribed 75.08 times overall by the time bidding ended on August 27, 2026.

The issue opened on August 24 and was available for subscription through August 27. Fresh applications can no longer be placed, as the bidding window has now closed.

The biggest push came from qualified institutional buyers (QIBs), whose portion was subscribed 181.20 times. Non-institutional investors (NIIs) also showed strong interest, with their category subscribed 77.56 times, while the retail portion ended at 13.69 times.

Employee investors subscribed 16.32 times.

Symbiotec Pharmalab IPO Subscription Status

As of the final subscription update on August 27 at around 5:14 PM, the IPO had received bids for 93,54,86,175 shares against 1,24,60,533 shares offered to eligible investors, resulting in an overall subscription of 75.08 times.

The QIB segment clearly stood out on the closing day, ending with more than 181 times the shares available. The NII category also saw heavy bidding, while retail participation remained comparatively moderate despite still crossing 13 times.

Day-Wise Symbiotec Pharmalab IPO Subscription Trend

The subscription pace changed dramatically over the four-day issue period. The IPO started relatively slowly on Day 1 but picked up pace as the bidding window progressed.

The final day made the biggest difference. QIB subscription jumped from 0.62x at the end of Day 3 to 181.20x by the close, while the overall subscription climbed from 5.62x to 75.08x.

Symbiotec Pharmalab IPO Details

Symbiotec Pharmalab’s IPO had a total issue size of ₹1,757 crore. This included a fresh issue of 15.21 lakh shares worth ₹150 crore and an offer for sale of 1.63 crore shares worth ₹1,607 crore.

The price band was fixed at ₹938 to ₹988 per share, with the final issue price set at ₹988 per share. The IPO lot size was 15 shares, meaning retail investors needed a minimum investment of ₹14,820 at the upper end of the price band.

The company also reserved 33,408 shares for employees, who were offered a discount of ₹90 per share to the issue price.

Key IPO Details

Symbiotec Pharmalab IPO Key Dates

IPO Open: August 24, 2026

IPO Close: August 27, 2026

Allotment: August 28, 2026

Refund: August 31, 2026

Credit of Shares: August 31, 2026

Listing: September 1, 2026

The allotment is expected to be finalised on August 28. Investors who do not receive shares should see the refund process begin on August 31, while successful applicants are expected to receive shares in their demat accounts on the same day.

About Symbiotec Pharmalab

Symbiotec Pharmalab Ltd. was incorporated in 2002 and operates in the pharmaceutical and biotechnology space. The company develops and manufactures active pharmaceutical ingredients (APIs), nutritional ingredients and specialty products for customers in India as well as international markets.

With more than three decades of industry experience, the company has grown from a lab-scale steroidal hormone API manufacturer into an industrial-scale, backward-integrated manufacturing platform. Its products and facilities have received approvals from regulatory bodies including the US FDA and EU-GMP, along with regulators in South Korea and other markets.

Conclusion

The Symbiotec Pharmalab IPO closed on a strong note, with the overall issue ending at 75.08 times subscription. Institutional demand was the standout feature, with the QIB category reaching 181.20x, while the NII portion also crossed 77 times.

With the subscription window now closed, the focus shifts to the IPO allotment on August 28 and the expected listing on September 1. The final outcome for applicants will depend on the allotment process, particularly given the exceptionally high level of demand in the QIB and NII segments.

Source:

• https://www.nseindia.com/market-data/issue-information?symbol=SYMBIOTEC&series=EQ&type=Active